Fresenius SE (FSNUY) Lifted to Strong-Buy at Zacks Investment Research

Fresenius SE (NASDAQ:FSNUY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report issued on Friday, August 4th. The brokerage presently has a $24.00 target price on the stock. Zacks Investment Research‘s price objective points to a potential upside of 16.67% from the stock’s previous close.

According to Zacks, “Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company’s business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. “

Shares of Fresenius SE (FSNUY) traded down 1.90% during trading on Friday, hitting $20.18. The stock had a trading volume of 16,864 shares. Fresenius SE has a 52-week low of $17.22 and a 52-week high of $22.30.

WARNING: “Fresenius SE (FSNUY) Lifted to Strong-Buy at Zacks Investment Research” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at

About Fresenius SE

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Get a free copy of the Zacks research report on Fresenius SE (FSNUY)

For more information about research offerings from Zacks Investment Research, visit

What are top analysts saying about Fresenius SE? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius SE and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit